|
|
| Type |
Poster Presentation |
| Area |
의약화학 |
| Room No. |
포스터발표장 |
| Time |
4월 20일 (목요일) 11:00~12:30 |
| Code |
MEDI.P-448 |
| Subject |
Development of Novel Anti-Hepatitis C Virus Agent Targeting NS5A |
| Authors |
정유진, LIHUA1, 강순방1, 이정태, 금교창2,*
한림대학교 화학과, Korea
1한국과학기술연구원(KIST) 뇌의약연구단, Korea
2한국과학기술연구원(KIST) 케모인포메틱스연구센터, Korea
|
| Abstract |
Hepatitis C virus (HCV) is a leading cause of acute and chronic liver disease. About 180 million people are infected with HCV, which can lead to liver cirrhosis, hepatocellular carcinoma and consequently death. In addition to NS5B and NS3/4A protease inhibitor, NS5A was proved to be a promising target for the treatment of HCV. Several NS5A inhibitors such as BMS-790052 were launched recently and some were under clinical trials. We prepared a series of NS5A inhibitors possessing new scaffold and evaluated their activities against HCV cell lines. Among them, several compounds showed potent anti-HCV activity. Herein, we present anti-HCV activity of the hit compounds against various HCV genotypes and resistant strains mutated at L31V, Y93H of NS5A. |
| E-mail |
monodica@kist.re.kr |
|
119th General Meeting of the KCS